Oligonucleotide primers for mutagenesis were synthesized by Operon Technologies. Taq and Pfx DNA polymerases, restriction endonucleases, and bacteriophage T4 DNA ligase were purchased from Invitrogen. Cloning vectors (pET) were obtained from Novagen. Gel extraction, plasmid mini-prep, and PCR purification kits were purchased from Qiagen. All strains were grown in media acquired from Difco laboratories. Other items procured include isopropyl-1-thio-D-galactopyranoside (CalBiochem), iodoacetamide (Acros Organics), and tris(2-carboxyethyl) phosphine hydrochloride (Aldrich).
Taq DNA polymerase, Platinum Taq DNA polymerase, and/or Platinum Pfx DNA polymerase were used.
The template forward and reverse primers for halA1 were designed with NdeI and XhoI restriction sites (indicated in bold font), respectively, as A1FP: 5'-GCGCCGCATATGACAAATCTT-3' and A1RP: 5'-AGGCTCGAGTTAGTTGCAAGA-3'. The mutant forward primers for halA1-Xa mutant genes were as follows (nucleotide changes indicated by the underlined font, amino acid changes indicated in parentheses): 5'-GGTACAACATCAGCGCCCGTCTAGGTAAC-3' (C8A), 5'-CAAAGGTGCT-TACGCCACACTTACAGTTGAGTG-3' (C17A), 5'-GCACACTTACAGTTGCGTG-CATGCC-3' (E22A), 5'-GCACACTTACAGTTCAGTGCATGCCTTCTTGC-3' (E22Q), 5'-CACTTACAGTTGAGGCCATGCCTTCTTGC-3' (C23A). The above forward mutant primers were used with template reverse primer A1RP to amplify the 3' end of the partial halA1-Xa mutant genes. The 5' end of the partial halA1-Xa mutant genes were amplified using the template forward primer A1FP and the corresponding reverse-complementary mutant reverse primers. Successful reactions were purified by gel electrophoresis (2% agarose) and isolated using the QIAquick Gel Extraction Kit (Qiagen). The second rounds of PCR amplifications were performed using the PCR products generated during the first rounds, namely the 5' ends and 3' ends of the partial halA1-Xa mutant genes. Overlap extension PCR was carried out on a 100 µL scale with the 5' end and the 3' end of the partial halA1-Xa mutant gene products. Reactions also included deoxyribonucleotides (0.25 mM each), MgSO 4 (1 mM), 2x Pfx DNA polymerase amplification buffer, and Pfx DNA polymerase. The linear amplification included six cycles of denaturing, annealing, and extending in the absence of A1FP and A1RP. Following the linear amplification, A1FP (1.5 µM) and A1RP (1.5 µM) were added and twenty-four additional cycles under the same conditions were used to amplify the full halA1-Xa mutant gene. Successful reactions were purified by gel electrophoresis (2% agarose) and isolated using the QIAquick Gel Extraction Kit. The final PCR products were digested with NdeI and XhoI restriction enzymes then ligated into the pET15b vector digested with the same enzymes. The desired mutations were verified by DNA sequencing.
The template forward and reverse primers for halA2 were designed with NdeI and XhoI restriction sites (indicated in bold font), respectively, as A2FP: 5'-GCGCCGCATATGGTAAATTCA-3' and A2RP: 5'-AAACTCGAGTTAGCACTGGCT-3'. The mutant forward primers for halA2-Xa mutant genes were as follows (nucleotide changes indicated by underlined font, amino acid changes indicated in parentheses): 5'-CGTACAACTTGGCCTGCCGCTACAGTTGGTGTCTCC-3' (C5A), 5'-CTCCGTAGCCTT-GGCCCCAACTACAAAG-3' (C15A), 5'-CCTTGTGCCCAACTGCAAAGTGTACAAGCC-3' (T18A), 5'-GCCCAACTACAAAGGCTACAAGCCAGTGC-3' (C20A), 5'-CAAAGTGTACAGCCCAGTGCTAACTCGAGG-3' (S22A). These forward mutant primers were used with template reverse primer A2RP to amplify the 3' end of the partial halA2-Xa mutant genes. The 5' end of the partial halA2-Xa mutant genes were amplified using the template forward primer A2FP and the corresponding reverse-complementary mutant reverse primers. Successful reactions were purified by gel electrophoresis (2% agarose) and isolated using the QIAquick Gel Extraction Kit. The second rounds of PCR amplifications were performed using the PCR products generated during the first rounds, namely the 5' ends and 3' ends of the partial halA2-Xa mutant genes. Overlap extension PCR was carried out on a 100 µL scale with the 5' end and the 3' end of the partial halA2-Xa mutant gene products using the primers A2FP and A2RP as similarly described above. The desired mutations were verified by DNA sequencing.
The expression vector pET15b-halA2 (McClerren et al., 2006) was utilized as a template for the construction of pET15b-halA2-XaGS. The first round of PCR was carried out as described above using the mutant forward primer (Factor Xa cleavage site in bold font): 5'-CTAGCTGGTTCAATTGAAGGTCGTGGAGATGTGCAT-3' and the template reverse primer A2RP to amplify the 3' end of the partial halA2-XaGS mutant gene. The 5' end of the partial halA2-XaGS mutant gene was amplified using the template forward primer A2FP and the corresponding reverse-complementary mutant reverse primer. Successful reactions were purified by gel electrophoresis (2% agarose) and isolated using the QIAquick Gel Extraction Kit. The second round of PCR amplification was performed using the PCR products generated during the first round, namely the 5' end and 3' end of the partial halA2-XaGS mutant gene. Overlap extension PCR was carried out as described above. Successful reactions were purified by gel electrophoresis (2% agarose) and isolated using the QIAquick Gel Extraction Kit. The final PCR product was digested with NdeI and XhoI restriction enzymes then ligated into the pET15b vector digested with the same enzymes. The desired mutations were verified by DNA sequencing.
Four mutants were constructed using only one round of PCR because the mutation site was close to the 3' end of the gene. PCR amplifications were carried out with template forward primer (0.5 µM) and mutant reverse primer (0.5 µM). Reactions also included deoxyribonucleotides (0.25 mM each), MgCl 2 (1.5 mM), and 1x PCR reaction buffer, and Taq DNA polymerase. Each mutant reverse primer included the mutation (indicated in underlined font) and the XhoI restriction site (indicated in bold font). The halA1-Xa S26A gene was amplified using the template forward primer A1FP and the HalA1-Xa S26A mutant reverse primer: 5'-TATAGGATCCTCGAGTTAGTTGCAAGCAGGCATG-3' with the plasmid pET15b-halA1-Xa as the template. The halA1-Xa C27A gene was amplified using the template forward primer A1FP and the HalA1-Xa C27A mutant reverse primer: 5'-TATAGGATCCTCGAGTTAGTTGGCAGAAGGCATG-3' with the plasmid pET15b-halA1-Xa as the template. The halA2-Xa C24A gene was amplified using the template forward primer A2FP and the HalA2-Xa C24A mutant reverse primer: 5'-TATAGGATCCTCGAGTTAGGCCTGGCTTGTAC-3' with the plasmid pET15b-halA2-Xa as the template. The halA2-XaGS Q23A gene was amplified using the template forward primer A2FP and the HalA2-XaGS Q23A mutant reverse primer: 5'-CCGCTCGAGTTAGCATGCGCTTGTACA -3' with the plasmid pET15b-halA2-XaGS as the template. Successful reactions were purified by gel electrophoresis (2% agarose) and isolated using the QIAquick Gel Extraction Kit. The final PCR products were digested with NdeI and XhoI restriction enzymes then ligated into the pET15b vector digested with the same enzymes. The desired mutations were verified by DNA sequencing.
Bioactivity Studies on Mutants of the B-Ring of Halα
Given the unexpected outcome of the bioactivity studies of the Halα mutant with a disrupted Bring, the experiment was repeated more two times. Each time, a newly sequenced plasmid confirming the mutation was used to transform E. coli BL21 (de3), a single colony was picked and used for overexpression of the HalA1 mutant peptide. After IMAC purification, the mass of the mutant peptide was confirmed and the peptide was subjected successively to HalM1 and Factor Xa treatment. Each time the product had antimicrobial activity and no such activity was observed in controls in which one of the ingredients (HalM1, Factor Xa) was omitted. (C) HalA1-Xa S26A treated with TCEP/IAA before (red line) and after incubation with HalM1 (blue line).
A.
(D) HalA2-Xa T18A treated with TCEP/PHMB before (red line) and after incubation with HalM2 (blue line).
(E) HalA2-Xa S22A treated with TCEP/PHMB before (red line) and after incubation with HalM2 (blue line).
HalA1-Xa HalM1 Dehydration
B.
HalA1-Xa HalM1 Cyclization Note that dehydration of this mutant is less efficient resulting in both 6-fold and 7-fold dehydrated product. In addition, panel D clearly shows that cyclization is also severely impaired as the peak for 7-fold dehydration without any PHMB adduct is a very minor component of the assay products. 
